Tag: chemotherapy

GSK announces significant survival results for Jemperli in endometrial cancer trial

businessnewstoday- March 18, 2024

In a significant development for patients with primary advanced or recurrent endometrial cancer, GSK plc (LSE/NYSE: GSK) has disclosed promising outcomes for Jemperli (dostarlimab-gxly) from ... Read More

Advancing bladder cancer treatment: EMA scrutinizes Astellas-Pfizer’s innovative therapy

businessnewstoday- January 28, 2024

A groundbreaking development in bladder cancer treatment is on the horizon as Astellas Pharma Inc. and Pfizer Inc. await the European Medicines Agency’s (EMA) review ... Read More

Venus Remedies expands cancer drug portfolio in South Eastern Europe

businessnewstoday- September 21, 2023

In a significant development for its oncology portfolio in South Eastern Europe, Venus Remedies Ltd has been granted marketing authorization from Serbia for chemotherapy drugs ... Read More

AstraZeneca, Daiichi Sankyo’s Enhertu approved for breast cancer in China

businessnewstoday- July 15, 2023

The National Medical Products Administration (NMPA) of China has granted approval to AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for use as a monotherapy in ... Read More

Gilead gets Trodelvy FDA approval for pre-treated HR+/HER2- metastatic breast cancer

Raghuram Kadari- February 10, 2023

Gilead Sciences has secured the approval of the US Food and Drug Administration (FDA) for Trodelvy (sacituzumab govitecan-hziy) for pre-treated HR+/HER2- metastatic breast cancer. The ... Read More

Gilead gets Trodelvy FDA priority review for pre-treated HR+/HER2- metastatic breast cancer

businessnewstoday- October 16, 2022

Gilead Sciences said that Trodelvy (sacituzumab govitecan-hziy) has been granted priority review from the US Food and Drug Administration (FDA) for the treatment of another ... Read More

AstraZeneca, Daiichi Sankyo get Enhertu FDA approval for HER2-low metastatic breast cancer

pallavi123- August 7, 2022

Enhertu FDA approval : AstraZeneca and Daiichi Sankyo have secured approval for Enhertu (trastuzumab deruxtecan) from the US Food and Drug Administration for the treatment ... Read More

Lantern Pharma gets FDA nod for Harmonic phase 2 clinical trial of LP-300

pallavi123- July 17, 2022

Lantern Pharma said that the US Food and Drug Administration (FDA) has authorized it to move ahead with its Harmonic phase 2 clinical trial of ... Read More

FDA rejects Lilly’s sintilimab as first line treatment of NSCLC

pallavi123- March 27, 2022

The US Food and Drug Administration (FDA) has rejected the biologics license application (BLA) of Eli Lilly and Company (Lilly)’s sintilimab injection in nonsquamous non-small ... Read More

Lupin signs agreement for biosimilar Pegfilgrastim in Brazil

pallavi123- December 4, 2021

Lupin Limited has signed an exclusive distribution and marketing agreement with Biomm SA for biosimilar Pegfilgrastim in Brazil. The Indian pharma company had earlier secured ... Read More